Telocyte is a biotechnology firm focused on the development of telomerase therapy to treat Alzheimer's disease as a strategic first target, with therapy for other age-related diseases to follow thereafter. Telomere biology has been recognized as having clinical potential for the past twenty years. Recent advances in both animal research and delivery systems have created an opportunity to create an unsurpassed clinical therapy.

**Telocyte** was founded in 2015 by Michael Fossel, Peter Rayson, and Leland Nolan. Dr. Fossel is known for his journal articles, lectures, and books on telomerase therapy, including the only textbook in this field, *Cells, Aging, and Human Disease* (Oxford University Press, 2004). Peter Rayson, the CEO, is based in the UK; Lee Nolan is based in the US. **Telocyte** is working in collaboration with the CNIO, Spain's national institute for oncology, and will be pursuing human trials under FDA auspices, aimed at curing Alzheimer's disease.